"What is liquid biopsy and how is it used in oncology?"

Gloved hand holding a dark red blood serum vial over a white lab bench, with a genomic sequencer blurred in the background.

Liquid biopsy is a minimally invasive diagnostic technique that detects cancer-related biomarkers circulating in a patient’s blood or other bodily fluids without the need for surgical tissue removal. It works by analyzing molecular signals shed by tumors into the bloodstream, making it possible to study cancer biology through a simple blood draw. The sections below explore how the method works, what it measures, and where it stands in oncology research today.

How does liquid biopsy detect cancer without surgery?

Liquid biopsy detects cancer by analyzing biological material that tumors release into the bloodstream. As tumor cells grow, divide, and die, they shed fragments of DNA, intact cells, and other molecular signals into circulation. A blood sample can capture these fragments, which are then isolated and analyzed using molecular techniques such as next-generation sequencing or digital PCR.

The key insight behind liquid biopsy is that tumors are not isolated structures. They constantly interact with the surrounding environment and, in doing so, leave a molecular trace in the blood. Researchers can examine this trace to identify genetic mutations, chromosomal abnormalities, or other alterations associated with malignancy.

Because the sample is a blood draw rather than a surgical procedure, liquid biopsy can be repeated at regular intervals. This makes it particularly valuable in research settings where tracking tumor dynamics over time is important, something that would be impractical with repeated surgical biopsies.

What types of biomarkers does liquid biopsy analyze?

Liquid biopsy analyzes several categories of cancer biomarkers found in blood and other body fluids. The most studied are circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles such as exosomes. Each biomarker type offers a different window into tumor biology.

The main biomarker categories include:

  • Circulating tumor DNA (ctDNA): Short fragments of DNA released by tumor cells into the bloodstream. ctDNA carries the same mutations as the tumor from which it originates, making it a direct molecular indicator of tumor activity.
  • Circulating tumor cells (CTCs): Intact cancer cells that have detached from a primary or metastatic tumor and entered circulation. CTCs can be cultured and studied to understand tumor behavior.
  • Extracellular vesicles and exosomes: Tiny membrane-bound particles released by cells, including tumor cells, that carry proteins, RNA, and DNA. These are being actively investigated as informative biomarkers.
  • Cell-free RNA (cfRNA): RNA molecules circulating in plasma that can reflect gene expression patterns in tumors.
  • Circulating proteins and metabolites: Molecular signals that may indicate tumor presence or activity, often studied alongside nucleic acid-based markers.

Among these, ctDNA has received the most research attention in oncology due to its direct genetic link to the tumor and its detectability using well-established sequencing technologies.

What is liquid biopsy used for in oncology today?

In oncology research today, liquid biopsy is primarily used to study tumor genetics, monitor disease progression, and investigate resistance mechanisms during cancer treatment research. It is being explored as a tool for early detection, molecular profiling, and tracking how tumors evolve over time.

Researchers apply liquid biopsy in several contexts:

  1. Early cancer detection research: Scientists are investigating whether ctDNA and other circulating biomarkers can signal tumor presence before conventional imaging detects a mass.
  2. Molecular tumor profiling: Liquid biopsy can reveal the mutational landscape of a tumor, helping researchers understand which genetic alterations are driving growth.
  3. Monitoring tumor dynamics: Serial blood sampling allows researchers to observe how the tumor’s molecular profile changes over time, including in response to experimental interventions.
  4. Studying treatment resistance: When tumors develop resistance, liquid biopsy can help identify the emerging mutations responsible, supporting research into next-generation therapeutic strategies.
  5. Minimal residual disease research: After treatment, ctDNA levels may indicate whether residual tumor cells remain, a question of significant interest in translational oncology.

In the Benelux region, academic research groups and biotech companies are actively incorporating liquid biopsy into their oncology workflows, reflecting broader European interest in this approach.

What’s the difference between liquid biopsy and tissue biopsy?

The key difference between liquid biopsy and tissue biopsy is the sample source. Tissue biopsy removes a physical piece of tumor through a surgical or needle-based procedure, while liquid biopsy analyzes biomarkers circulating in blood or other body fluids. Each approach has distinct research advantages and practical trade-offs.

Tissue biopsy provides a direct, spatially defined sample from the tumor. Researchers can examine cellular architecture, protein expression, and genetic content in a localized context. However, it captures only a snapshot of one part of the tumor at one point in time, which may not reflect the full genetic diversity of a heterogeneous tumor.

Liquid biopsy, by contrast, integrates signals from multiple tumor sites simultaneously, since DNA and cells from different parts of a tumor all enter the same bloodstream. This makes it potentially more representative of overall tumor heterogeneity. It also enables repeated sampling without the burden of repeated surgical procedures.

The two approaches are increasingly viewed as complementary rather than competing. Tissue biopsy remains the standard for initial diagnosis and histological characterization, while liquid biopsy is being investigated as a dynamic, longitudinal monitoring tool in research settings.

What are the current limitations of liquid biopsy?

Liquid biopsy faces several important limitations that researchers are actively working to address. The most significant is sensitivity: ctDNA and other circulating biomarkers are present in very low concentrations, particularly in early-stage cancers, making reliable detection technically challenging.

Additional limitations include:

  • Specificity challenges: Not all circulating DNA fragments originate from tumors. Non-tumor sources, including normal cell turnover and inflammatory processes, can complicate interpretation.
  • Tumor heterogeneity: While liquid biopsy can capture signals from multiple tumor sites, it may still miss subclonal mutations present in only a small fraction of tumor cells.
  • Standardization gaps: Pre-analytical variables such as blood collection methods, processing protocols, and storage conditions can affect results, making cross-study comparisons difficult.
  • Analytical variability: Different sequencing platforms and bioinformatics pipelines can yield different results from the same sample, underscoring the need for validated, reproducible workflows.
  • Biological interpretation: Identifying a mutation in ctDNA is only the first step. Understanding its functional significance in the context of a specific tumor type requires additional biological knowledge.

These limitations do not diminish the promise of liquid biopsy, but they highlight why continued methodological refinement and rigorous research validation remain essential before broader conclusions can be drawn.

What role does liquid biopsy play in the future of precision oncology?

Liquid biopsy is a promising approach for the future of precision oncology because it has the potential to make tumor molecular profiling faster, less invasive, and more dynamic. As sequencing technologies improve and analytical sensitivity increases, liquid biopsy may become a routine research and diagnostic tool for characterizing tumors at the molecular level.

The concept of precision oncology relies on matching research and therapeutic strategies to the specific molecular features of an individual’s tumor. Liquid biopsy supports this by providing a real-time view of tumor genetics that can evolve as the disease progresses. This is particularly relevant in research into acquired resistance, where tumors develop new mutations that alter their biological behavior.

In 2026, research groups across Europe, including in the Benelux region, are investigating multi-analyte liquid biopsy panels that combine ctDNA analysis with protein markers, methylation patterns, and RNA signals. The goal is to increase both sensitivity and specificity by integrating multiple layers of molecular information into a single test.

Longer term, liquid biopsy may contribute to population-level cancer research by enabling large-scale biobanking of longitudinal blood samples. This kind of data infrastructure could accelerate the discovery of new cancer biomarkers and deepen understanding of how tumors evolve across diverse patient populations.

How BioSPX supports liquid biopsy research

Liquid biopsy workflows depend on high-quality instrumentation at every stage, from sample preparation and nucleic acid isolation to detection and quantification of low-abundance biomarkers. BioSPX supports research laboratories in the Benelux region with the instruments and expertise needed to build and optimize these workflows.

  • Multimode readers and imaging systems for biomarker detection and cellular analysis
  • Liquid handling solutions that improve reproducibility in low-volume sample processing
  • Microplate washers and dispensers for high-throughput assay preparation
  • Expert product specialists who advise on instrument configuration and experimental setup
  • Installation, training, and maintenance support from a dedicated service department

Whether you are setting up a ctDNA detection workflow or scaling up a circulating tumor cell assay, BioSPX’s team can help you select the right instruments for your research goals. Contact BioSPX to discuss your liquid biopsy research needs.

Frequently Asked Questions

How much blood is typically needed for a liquid biopsy, and how often can samples be collected?

Most liquid biopsy protocols require between 5 and 20 mL of blood, depending on the biomarker being analyzed and the sensitivity of the detection platform. Because the procedure is as routine as a standard blood draw, samples can be collected at regular intervals — weekly, monthly, or at clinically defined timepoints — without placing significant burden on the patient or research participant. This repeat-sampling capability is one of liquid biopsy’s most important advantages for longitudinal oncology research.

What sequencing technologies are most commonly used to analyze ctDNA, and how do I choose between them?

The two most widely used approaches are next-generation sequencing (NGS) and digital PCR (dPCR), including droplet digital PCR (ddPCR). NGS offers broad mutational profiling across many genomic regions simultaneously, making it well suited for discovery-phase research and tumor heterogeneity studies. Digital PCR, by contrast, provides extremely sensitive and quantitative detection of known mutations, making it the preferred choice when monitoring a specific variant over time. Your choice should be guided by whether your research goal is exploratory profiling or precise longitudinal quantification of a defined target.

What are the most common pre-analytical mistakes that can compromise liquid biopsy results?

The most frequent pre-analytical errors include using standard EDTA tubes instead of cell-free DNA-preserving collection tubes, delaying plasma separation beyond the recommended timeframe (typically 2–4 hours), and inconsistent centrifugation protocols that leave residual cellular contamination in the plasma. These variables can cause genomic DNA from lysed white blood cells to dilute or mask the ctDNA signal, dramatically reducing assay sensitivity and reproducibility. Establishing a strictly standardized sample collection and processing SOP before beginning a study is essential to generating reliable, comparable data.

Can liquid biopsy detect all cancer types equally well, or does performance vary by tumor type?

Performance varies considerably across cancer types, largely because ctDNA shedding rates differ between tumors. Cancers such as colorectal, lung, and pancreatic cancer tend to shed higher levels of ctDNA into the bloodstream, making them more amenable to liquid biopsy analysis. Brain tumors, by contrast, are partially shielded by the blood-brain barrier, resulting in very low ctDNA levels in peripheral blood and making detection more challenging. Researchers should account for tumor type, stage, and expected ctDNA shedding levels when designing their liquid biopsy studies and selecting appropriate assay sensitivity thresholds.

How should I validate a liquid biopsy assay before using it in a research study?

Assay validation should include assessments of analytical sensitivity (limit of detection), specificity, reproducibility, and concordance with matched tissue biopsy data where available. It is advisable to use reference standards with known allele frequencies — such as commercially available cell-free DNA reference materials — to benchmark your platform’s performance before applying it to patient samples. Running parallel testing across multiple operators and on different days will also help establish inter- and intra-assay variability. Documenting this validation rigorously is particularly important if your data will be submitted for publication or used in translational research contexts.

Is liquid biopsy only applicable to blood samples, or can other body fluids be used?

While blood plasma is by far the most commonly used matrix, liquid biopsy can also be applied to other body fluids, including urine, cerebrospinal fluid (CSF), pleural effusions, and saliva. CSF, for example, has shown promise for detecting ctDNA from central nervous system tumors at higher concentrations than peripheral blood, partially circumventing the blood-brain barrier limitation. Urine-based liquid biopsy is being explored for urological cancers such as bladder and kidney cancer. The choice of biofluid should be guided by the tumor type under investigation and the specific research question being asked.

What should I consider when scaling up a liquid biopsy workflow from a small pilot study to a larger cohort?

Scaling up introduces challenges around throughput, consistency, and data management that are less apparent at the pilot stage. Automated liquid handling systems become critical at this point, as manual pipetting of low-volume plasma samples introduces variability that compounds across large sample sets. You should also ensure your bioinformatics pipeline can handle increased sequencing data volumes and that your storage and chain-of-custody protocols are robust enough to maintain sample integrity across the full cohort. Engaging with instrument specialists early in the scale-up planning process can help you identify bottlenecks and configure the right combination of hardware and software before they become problems mid-study.

Related Articles

This content was generated with the help of AI and it may contain mistakes